

学会発表

<国際学会>

The Annual European Congress of Rheumatology 2020 (欧州リウマチ学会年次学術集会) (ワークショップ) フランクフルト、ドイツ (WEB)

1.T. Dörner, Y. Tanaka, M. A. Petri, J. S. Smolen, D. Wallace, B. Crowe, E. Dow, R. E. Higgs, G. Rocha, R. Benschop, M. Silk, S. De Bono, R. Hoffman, D. Fantini

「DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL」

2.E. F. Morand, R. Furie, Y. Tanaka, R. Kalyani, G. Abreu, L. Pineda, R. Tummala

「EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS」

3.Y. Tanaka, S. C. Bae, D. Bass, M. Chu, P. Curtis, K. Derose, B. Ji, R. Kurrasch, J. Lowe, P. Meizlik, D. Roth

「A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARS」

4.V. Bykerk, A. B. Gottlieb, K. Reich, Y. Tanaka, K. Winthrop, C. Popova, N. Tilt, A. Blauvelt

「DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA」

5. J. S. Smolen, L. Xie, B. Jia, P. C. Taylor, G. R. Burmester, Y. Tanaka, A. Elias, A. Cardoso, R. Ortmann, C. Walls, M. Dougados

「EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY」

6.A. Kivitz, Y. Tanaka, S. Lee, L. Ye, H. Hu, R. Besuyen, B. Combe

「FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY」

7. P. Emery, Y. Tanaka, V. Bykerk, C. Bingham, T. Huizinga, G. Citera, K. H. G. Huang, S. Connolly, Y. Elbez, R. Wong, K. Lozenski, R. Fleischmann

「MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY」

8. P. Emery, Y. Tanaka, V. Bykerk, T. Huizinga, G. Citera, C. Bingham, S. Banerjee, S. Connolly, J. Zhuo, R. Wong, K. H. G. Huang, K. Lozenski, Y. Elbez, R. Fleischmann

「MAINTENANCE OF SDAI REMISSION AND PATIENT-REPORTED OUTCOMES (PROS)」

FOLLOWING DOSE DE-ESCALATION OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+ PATIENTS WITH EARLY RA: RESULTS FROM AVERT-2, A RANDOMISED PHASE IIIB STUDY]

9.Y. Tanaka, Z. Li, N. Inanc, R. Xavier, N. Tilt, C. Cara, C. Saadoun, T. Takeuchi

[CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES]

10.G. R. Burmester, D. Aletaha, J. Pope, Y. Tanaka, P. Durez, A. Gomez-Centeno, A. Pechonkina, B. Bartok, F. Matzkies, L. Ye, Z. Yin, R. Besuyen, W. Rigby, B. Combe

[CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS]

11. B. Combe, A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campo, H. S. B. Baraf, U. Kumar, F. Matzkies⁸, B. Bartok, L. Ye, Y. Guo, C. Tasset, J. Sundry, A. Jahreis, N. Mozaffarian, R. B. M. Landewé, S. C. Bae, E. Keystone, P. Nash

[EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS]

12. H. Hao, S. Nakayamada, Y. Kaoru, N. Ohkubo, S. Iwata, Y. Tanaka

[IL-2 DRIVES THE CONVERSION OF T FOLLICULAR HELPER TO T FOLLICULAR REGULATORY CELLS THROUGH EPIGENETIC MODIFICATION IN SYSTEMIC LUPUS ERYTHEMATOSUS]

13. C. Pachai, S. Connolly, J. Landis, Y. Tanaka, V. Bykerk, T. Huizinga, G. Citera, C. Bingham, R. Wong, K. H. G. Huang, S. Du, W. Hayes, C. Wu, R. Fleischmann, P. Emery

[IMPACT OF BASELINE EROSION SCORE ON RESPONSE TO TREATMENT AND FUTURE RADIOLOGICAL DAMAGE IN AVERT-2, A RANDOMISED PHASE IIIB STUDY OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY-POSITIVE (ACPA+) PATIENTS WITH EARLY RA]

14. M. C. Genovese, K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye, D. Jiang, Y. Guo, B. Bartok, R. Besuyen, G. R. Burmester, J. E. Gottenberg

[INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS]

15. S. Johnson, R. Brinks, K. Costenbader, D. Daikh, M. Mosca, R. Ramsey-Goldman, J. S. Smolen, D. Wofsy, D. Boumpas, D. L. Kamen, D. Jayne, R. Cervera, N. Costedoat-Chalumeau, B. Diamond, D. D. Gladman, B. H. Hahn, F. Hiepe, S. Jacobsen, D. Khanna, K. Lerstrom, E. Massarotti, W. J. Mccune, G. Ruiz-Irastorza¹ J. Sanchez-Guerrero, M. Schneider, M. B. Urowitz, G. Bertsias, B. F. Hoyer, N. Leuchten, C. Tani, S. Tedeschi, Z. Touma, G. Schmajuk, B. Anic, F. Assan, T. Chan, A. E. Clarke M. K. Crow, L. Czirják, A. Doria, W. Graninger, B. Halda-Kiss², S. Hasni, P. Izmirly, M.

Jung, G. Kumanovics, X. Mariette, I. Padjen J. M. Pego-Reigosa, J. Romero-Diaz, I. Rua-Figueroa³
R. Seror, G. Stummvoll, Y. Tanaka, M. Tektonidou, C. Vasconcelos, E. Vital, D. J. Wallace, S.
Yavuz, P. L. Meroni⁴, M. Fritzler, R. Naden, T. Dörner, M. Aringer

「PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES」

16. S. B. Cohen, R. Van Vollenhoven, J. R. Curtis, L. Calabrese, C. Zerbini, Y. Tanaka, L. Bessette,
C. Schlacher, T. Shaw, J. Liu, J. J. Enejosa, Y. Song, G. R. Burmester

「SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS」

17. J. S. Smolen, P. Emery, W. Rigby, Y. Tanaka, J. Ignacio Vargas, N. Damjanov, M. Jain, Y. Song, N.
Khan, J. J. Enejosa, S. B. Cohen

「UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY」

18. M. Bergman, Y. Tanaka, G. Citera, S. Bahlas, M. Ali, S. Meerwein, Y. Song, V. Strand

「UPADACITINIB TREATMENT AND THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) AMONG PATIENTS WITH RHEUMATOID ARTHRITIS」

The 22nd Asia Pacific League of Associations for Rheumatology Congress WEB

19. Yoshiya Tanaka

「Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis in Asian Patients With an Inadequate Response to Methotrexate: Results from an Asian Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study」

The 22nd Asia Pacific League of Associations for Rheumatology Congress (APLAR アジアパシフィックリウマチ学会(ワークショップ) WEB

20. Yoshiya Tanaka

「Certolizumab Pegol in Patients with Rheumatoid Arthritis: Pooled Efficacy Analysis of Phase 3 Clinical Trials across Baseline Rheumatoid Factor Quartiles」

21. Yoshiya Tanaka

「Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 weeks from the SELECT-MONOTHERAPY Study」

22. Yoshiya Tanaka

「Biomarker Levels and Disease Control in Japanese and Korean Patients with SLE Receiving Belimumab: A Phase 3, 7-Year Continuation Study」

23. Yoshiya Tanaka

「Certolizumab Pegol In Japanese Patients With Early Rheumatoid Arthritis: Disease Activity And

Radiographic Progression Across Rheumatoid Factor Quartiles (C-Opera Study)】

24.Yoshiya Tanaka

「Demographic Features of IFN-Negative and Positive Patients With Systemic Lupus Erythematosus and Baricitinib-Induced Changes in Gene Expression」

25.Yoshiya Tanaka

「Efficacy and Safety of Filgotinib for Asian Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: FINCH1 Subgroup Analysis」

26.Yoshiya Tanaka

「Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA」

27.Yoshiya Tanaka

「Filgotinib for Asian Patients With Moderately/Severely Active Rheumatoid Arthritis: Pooled Safety Analysis of the Phase 3 FINCH Studies」

28.Yoshiya Tanaka

「Indirect Comparison of the Efficacy and Safety of Peficitinib (ASP015K), Baricitinib and Tofacitinib in Patients with Rheumatoid Arthritis」

The 22nd Asia Pacific League of Associations for Rheumatology Congress (APLAR アジアパシフィックリウマチ学会(教育講演) WEB

29.Yoshiya Tanaka

「The Role of Anti-TNFs in Preventing the Progression of Joint Damage in RA」

30.Yoshiya Tanaka

「Basic and Clinical of Rheumatology」

31.Yoshiya Tanaka

「Efficacy and Safety of Filgotinib for Patients with RA with Inadequate Response to MTX」

32.Yoshiya Tanaka

「Integrated safety analysis of Filgotinib treatment for RA from 7 clinical trials」

33.Yoshiya Tanaka

「Treatment practices and unmet needs in patients with SLE in the Asia-Pacific region」

The 22nd Asia Pacific League of Associations for Rheumatology Congress (APLAR アジアパシフィックリウマチ学会(シンポジウム) WEB

34.Yoshiya Tanaka

「To continue, taper or discontinue biologics - Implications on RA treatment outcomes」

2020 American College of Rheumatology (ACR) Annual Convergence WEB

35.Bernard Combe, Alan Kivitz² Yoshiya Tanaka, Désirée van der Heijde, J-Abraham Simon-Campos, Herbert S. Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal

- Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Robert Landewé, Sang-Cheol Bae, Edward C Keystone and Peter Nash
「Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results」
36. Josef Smolen, Paul Emery, William Rigby, Yoshiya Tanaka, Juan Vargas, Nemanja Damjanov, Manish Jain, Yanna Song, Nasser Khan, Jeffrey Enejosa and Stanley Cohen
「Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks」
37. Gerd Burmester, Vivian Bykerk, Maya Buch, Yoshiya Tanaka, Hideto Kameda, Amy Praetgaard, Hubert van Hoogstraten, Antonio Fernandez-Nebro and Thomas Huizinga
「Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis」
38. Eduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, Daniel Aletaha, Peter Taylor, In-Ho Song, Tim Shaw, Yanna Song, Ryan DeMasi, Mira Ali and Roy Fleischmann
「Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study」
39. Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Mark Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartok, Angelika Jahreis, Robin Besuyen, Gerd Burmester and Jacques-Eric Gottenberg
「Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years」
40. Stanley Cohen, Ronald F Van Vollenhoven, Jeffrey Curtis, Leonard Calabrese, Cristiano AF Zerbini, Yoshiya Tanaka, Louis Bessette, Casey Schlacher, Tim Shaw, John Liu, Jeffrey Enejosa, Yanna Song and Gerd Burmester
「Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis」
41. Yoshiya Tanaka, Hisashi Yamanaka, Leslie Harrold, Tin-chi Lin, Ekta Agarwal, Jose L Rivas, Naonobu Sugiyama, Jeffrey Greenberg and Mitsumasa Kishimoto
「Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness」
42. Mitsumasa Kishimoto, Yoshiya Tanaka, Leslie Harrold, Alina Onofrei, Christine Barr, Ekta Agarwal, Jose L Rivas, Naonobu Sugiyama, Jeffrey Greenberg and Hisashi Yamanaka
「Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety」
43. Paul Emery, Yoshiya Tanaka, Vivian Bykerk, Clifton Bingham III, Thomas Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Sean Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski and Roy Fleischmann
「Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study」

44. Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey R Curtis and Roy Fleischmann
「Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis」
45. Hisashi Yamanaka, Mitsumasa Kishimoto, Kazuhisa Nakano, Kenta Misaki, Yuji Yamanishi, Hiroaki Dobashi, Masamitsu Natsumeda, Toshiaki Miyamoto, Koichi Amano, Akira Sagawa, Norihiko Koido, Corrona Japan Consortium, Leslie Harrold, Tin-chi Lin, Jeffrey Greenberg and Yoshiya Tanaka
「International Comparison of Japanese and US Cross Country Utilization of RA Medications」
46. Thomas Dörner, Yoshiya Tanaka, Michelle Petri, Josef Smolen, Daniel Wallace, Brenda Crowe, Ernst Dow, Richard Higgs, Guilherme Rocha, Robert Benschop, Maria Silk, Stephanie de Bono, Robert Hoffman and Damiano Fantini
「Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial」
47. Alan Kivitz, Yoshiya Tanaka, Susan Lee, Lei Ye, Hao Hu, Robin Besuyen and Bernard Combe
「Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate」
48. Désirée van der Heijde, Cynthia E Kartman, Li Xie Scott Beattie, Douglas Schlichting, Patrick Durez, Yoshiya Tanaka and Roy Fleischmann
「Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND2020」

<国内学会>

1. 第 64 回日本リウマチ学会総会・学術集会(シンポジウム) WEB 開催

Yoshiya Tanaka

「筋炎治療戦略の新展開: 臨床試験の結果から」

- 第 64 回日本リウマチ学会総会・学術集会(教育講演) WEB 開催

2. Yoshiya Tanaka

「New perspectives on treatment of rheumatoid arthritis by JAK inhibitors」

3. Yoshiya Tanaka

「State-of-the-art progress in T cell-targeting treatment for rheumatoid arthritis」

- 第 64 回日本リウマチ学会総会・学術集会(ワークショップ) WEB 開催

7. Yoshiya Tanaka, Josef S Smolen, Paul Emery, William Rigby, Juan Ignacio Vargas, Nemanja Damjanov, Manish Jai, Yunxia Sui, Jeffrey Enejosa, Aileen L Pangan, Heidi S Camp, Stanley B Cohen

「Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 weeks from the SELECT-MONOTHERAPY Study」

5.Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Shinichi Asabe, Masayuki Yokoyama, Sebastian Meerwein, Yoshiya Tanaka

「The long-term safety and efficacy of upadacitinib (UPA) in Japanese patients (pts) with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs): 84-week results from SELECT-SUNRISE」

6.Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, Toshihiro Nanki, Hisanori Umehara, Nobuyuki Yasuda, Fumitoshi Tago, Makoto Kawakubo, Yasumi Kitahara, Tetsu Kawano, Toshio Imai

「Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 study」

7.Yoshiya Tanaka, Stanley B Cohen, Ronald Van Vollenhoven, Kevin L Winthrop, Cristiano Zerbini, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Gerd R Burmester

「SAFETY PROFILE OF Upadacitinib IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM」

8.Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, Nasser Khan, Ying Zhang, Tsutomu Takeuchi

「Safety profile of upadacitinib (UPA) in Japanese patients (pts) with rheumatoid arthritis (RA)」

9.Kayoko Kaneko, Nobuya Abe, Hideyuki Iwai, Yasunori Iwata, Kae Onishi, Takayuki Kishi, Yumi Shimada, Tsuyoshi Shirai, Yumi Tsuchida, Shingo Nakayamada, Nao Nishina, Takuya Nemoto, Toru Hirano, Yoko Miura, Mayuko Moriyama, Nobuyuki Yajima, Kenji Oku, Tsutomu Takeuchi, Yoshiya Tanaka, Keishi Fujio, Masakazu Matsushita, Takako Miyamae, Takashi Wada, Atsuko Murashima

「The effects of disease activity, organ damage and treatment at the time of diagnosis on the quality of life with young patients with SLE」

10.Tsutomu Takeuchi, Tomoko Ishizuka, Minako Sato, Yasushi Takita, Terence Rooney, Yoshiya Tanaka

「Pain Improvement in Japanese Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo」

Masayoshi Harigai, Tsutomu Takeuchi, Minako Sato, Atsushi Nishikawa, Yasushi Takita, Masaru

11.Tanaka, Yoshiya Tanaka

「Long-term Safety (up to 7 years [yrs]) of Baricitinib (Bari) in Patients (pts) including Japanese (JP) with Moderate to Severe Active Rheumatoid Arthritis (RA): an Integrated Analysis」

12.Takako Miyamae, Kayoko Kaneko, Nobuya Abe, Hideyuki Iwai, Yasunori Iwata, Kae Onishi, Takayuki Kishi, Yumi Shimada, Tsuyoshi Shirai, Yumi Tsuchida, Shingo Nakayamada, Nao Nishina, Takuya Nemoto Toru Hirano, Yoko Miura, Mayuko Moriyama, Nobuyuki Yajima, Kenji Oku, Tsutomu Takeuchi, Yoshiya Tanaka, Keishi Fujio, Masakazu Matsushita, Takashi Wada, Atsuko Murashima

「A Prospective cohort study on the short and long-term prognosis, including pregnancy outcomes, of

patients with systemic lupus erythematosus in Japan (PLEASURE-J study): Interim report of childhood-onset patients]

13. Yoshiya Tanaka, Toshiya Takahashi, Kazuteru Wada, Mariko Sumi, Owen Hagino, Hubert Van Hoogstraten, Michael C Nivens, Naoto Kato, Hideto Kameda

「Immunogenicity of sarilumab, a fully human IgG1 monoclonal antibody against the IL-6 receptor, in two phase 3 trials in patients (pts) with active rheumatoid arthritis (RA) (KAKEHASI and HARUKA)」

14. Yoshiya Tanaka, Toshiya Takahashi, Kazuteru Wada, Mariko Sumi, Owen Hagino, Hubert Van Hoogstraten, Michael C Nivens, Naoto Kato, Hideto Kameda

「Efficacy of sarilumab plus methotrexate (MTX) in patients (pts) with active rheumatoid arthritis (RA): subgroup analysis by baseline characteristics in a phase 3 trial (KAKEHASI)」

15. Yoshiya Tanaka, Hisashi Yamanaka, Tomohiro Hirose, Shigeyuki Toyozumi, Tsutomu Takeuchi

「An Analysis of Biological Markers Predicting Tofacitinib Efficacy in Japanese Patients with Rheumatoid Arthritis」

16. Tsutomu Takeuchi, Yoshiya Tanaka, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato, Désirée Van Der Heijde

「Peficitinib (ASP015K) in Combination with Methotrexate (MTX) Inhibits Joint Destruction in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate: A Japanese, Randomized, Double-Blind, Placebo-Controlled Trial (RAJ4)」

17. Tsutomu Takeuchi, Yoshiya Tanaka, Hiroyuki Izutsu, Yuichiro Kaneko, Neil M Schultz

「Minimal clinically important difference (MCID) achievement in patient-reported outcomes (PRO) in RAJ4, a randomized, double-blind, placebo-controlled study of peficitinib (PEF, ASP015K) in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX)」

18. Yoshiya Tanaka¹, Hiroyuki Okumura², Soyoung Kim³, Julie Dorey⁴, Piotr

Wojciechowski⁵, Neil M Schultz⁶

「Comparative Efficacy and Safety of Peficitinib (ASP015K) Versus Other Janus Kinase (JAK) Inhibitors for the Treatment of Patients with Rheumatoid Arthritis (RA): A Network Meta-Analysis (NMA)」

19. Yoshiya Tanaka, Tsutomu Takeuchi, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato

「Pooled Safety Findings in Japanese, Korean and Taiwanese Adult Patients with Rheumatoid Arthritis (RA) Treated with Peficitinib (ASP015K), a Janus Kinase (JAK) Inhibitor, for up to 6 Years」

20. Yoshiya Tanaka, Damon Bass, Beulah Ji, David Roth, Holly Quasny, Regina Kurrasch, Sally Egginton, Kathleen Derose

「Pooled Safety Findings in Japanese, Korean and Taiwanese Adult Patients with Impact of belimumab on renal outcomes in patients with systemic lupus erythematosus (SLE) located in North-East Asia (China, Japan and South Korea)」

21. Yoshiya Tanaka, Claire Barrett, Yuji Hirano, Kei Ikeda, Kathy Paizis, Carine Saadoun

「Anti-TNF Treatments for Women with Chronic Rheumatic Diseases: A Comparison of Attitudes and Perceptions of Clinicians in Japan and Australia」

22. Yuichi Ishikawa, Kazuhisa Nakano, Hiroko Miyata, Yoshiya Tanaka

「Estimation of treatment and prognostic factors of pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTD-PCP): an analysis of a national administrative database in Japan」

23. Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Ying Guo, Chantal Tasset, Angelika Jahreis, John S Sundry, Tsutomu Takeuchi

「24 Weeks Safety and Efficacy of Filgotinib in Japanese Patients Enrolled in a Global Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate」

24. Yoshiya Tanaka, Jean Sibilia, Arthur Kavanaugh, René R Westhovens, Kevin L Winthrop, Susan J Lee, Joy M Greer, Adam Dezure, Di An, Lei Ye, John S Sundry, Robin Besuyen, Luc Meuleners, Rieke Alten, Mark C Genovese

「Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study」

25. Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Beatrix Bartok, Franziska Matzkies, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Ying Guo, Chantal Tasset, Angelika Jahreis, John S Sundry, Tsutomu Takeuchi

「24 Weeks Safety and Efficacy of Filgotinib in Japanese Patients Enrolled in a Global Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Naïve to MTX Therapy」

26. Yoshiya Tanaka, Edward Keystone, Kevin L Winthrop, Mark C Genovese, Bernard G Combe, Alan Kivitz, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S Sundry, René R Westhovens, William Rigby, Gerd R Burmester

「Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis」

第 64 回日本リウマチ学会総会・学術集会 WEB 開催

27. Masataka Torigoe, Keisuke Maeshima, Takashi Ozaki, Yuichi Omura, Yoshiya Tanaka, Koji Ishii, Hirotaka Shibata

「Amino acid transporter Slc7a5 provides a novel strategy to regulate human B-cell activity」

28. Tsutomu Takeuchi, Yoshiya Tanaka, Hiroyuki Izutsu, Yuichiro Kaneko, Neil M Schultz

「Patient-reported Outcomes from RAJ4, A Randomized, Double-blind, Placebo-controlled Study of Peficitinib (PEF, ASP015K) in Patients with Rheumatoid Arthritis (RA) with An Inadequate Response to Methotrexate (MTX)」

29. Tsutomu Takeuchi, Yoshiya Tanaka, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato

「Serious Infection Rates in Japanese, Korean and Taiwanese Adult Patients with Rheumatoid Arthritis (RA) Treated with Peficitinib (ASP015K), a Janus Kinase (JAK) Inhibitor: Pooled Safety Findings up

to 6 Years of Treatment」

30. Tsutomu Takeuchi, Yoshiya Tanaka, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato

「Herpes Zoster-Related Disease Rates in Japanese, Korean and Taiwanese Adult Patients with

Rheumatoid Arthritis (RA) Treated with Peficitinib (ASP015K), a Janus Kinase (JAK) Inhibitor: Pooled Safety Findings up to 6 Years of Treatment]

31. Yoshiya Tanaka, Kohei Hagimori, Minako Sato, Yasushi Takita, Terence Rooney

「Improvements in Disease Activities (LDA and Remission) in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo]

32. He Hao, Shingo Nakayamada, Kaoru Yamagata, Naoaki Ohkubo, Shigeru Iwata, Yoshiya Tanaka

「IL-2 restores the balance of circulating T_h and T_{fr} cells in systemic lupus erythematosus]

33. Kaoru Yamagata, Shingo Nakayamada, Tong Zhang, Gulzhan Trimova, Phuong Anh Nguyen,

Fumi Uemura, Ipeei Miyagawa, Shigeru Iwata, Yoshiya Tanaka

「A novel role of epigenetic dysregulation of ubash3a in the pathogenesis of rheumatoid arthritis (RA)]

34. Naoaki Ohkubo, Yusuke Miyazaki, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro

Hanami, Shunsuke Fukuyo, Ipeei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Hiroko Yoshinari, Yoshiya Tanaka

「Involvement of Th22 cells in the pulmonary fibrosis and microvascular damage in patients with systemic sclerosis (SSc)]

35. Yasuyuki Todoroki, Satoshi Kubo, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro

Hanami, Shunsuke Fukuyo, Ipeei Miyagawa, Akio Kawabe, Yusuke Miyazaki, Yurie Kanda, Minoru Satoh, Kazuyoshi Saito, Yoshiya Tanaka

「Significance of nailfold videocapillaroscopy (NVC) in patients with mixed connective tissue disease (MCTD) differs from systemic sclerosis (SSc)]

36. Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami,

Shunsuke Fukuyo, Ipeei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Hiroko Yoshinari, Kazuyoshi Saito, Yoshiya Tanaka

「Combination of abatacept with low dose methotrexate was comparable to abatacept monotherapy in patients with rheumatoid arthritis]

37. Yoshino Inoue, Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro

Hanami, Shunsuke Fukuyo, Ipeei Miyagawa, Yusuke Miyazaki, Akio Kawabe, Hiroko Yoshinari, Yoshiya Tanaka

「Fractalkine receptor (CX3CR1) positive helper T cells characterize IgG4-related disease (IgG4-RD)]

38. Hiroko Yoshinari, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami,

Shunsuke Fukuyo, Ipeei Miyagawa, Satoshi Kubo, Ayako Yamaguchi, Yusuke Miyazaki, Akio Kawabe, Naoaki Ohkubo, Yoshino Inoue, Yurie Satoh, Yasuyuki Todoroki, Hiroko Miyata, Yoshiya Tanaka

「Impact of belimumab on immunophenotypic features in patients with systemic lupus erythematosus. ~LOOPS registry~]

39. Ayako Yamaguchi, Shintaro Hirata, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Yuko Kaneko, Tsutomu Takeuchi, Koichi Amano, Naoki Iwamoto, Atsushi Kawakami, Miho Murakami, Norihiro Nishimoto, Tatsuya Atsumi, Takayuki Sumida, Tsuneyo Mimori, Hisashi Yamanaka, Keishi Fujio, Kazuhisa Nakano, Yoshiya Tanaka
「Possibility of drug free remission after sustained remission in patients with RA.
-The two-year results of the FREE-J study, a real world prospective and observational cohort study.]
40. Akio Kawabe, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Satoshi Kubo, Ayako Yamaguchi, Yusuke Miyazaki, Hiroko Yoshinari, Yoshiya Tanaka
「Safety of biologic disease-modifying antirheumatic drugs and remission induction strategy in elderly patients with rheumatoid arthritis from the FIRST registry」
41. Yusuke Miyazaki, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Hiroko Yoshinari, Yoshino Inoue, Naoaki Ohkubo, Yoshiya Tanaka
「Effects of tocilizumab on immunophenotypic features in patients with large vessel vasculitis: 6-month results of FLOW study」
42. Shigeru Iwata, Mingzeng Zhang, Maiko Hajime, Gulzhan Trimova, Naoaki Ohkubo, Kazuhisa Nakano, Shingo Nakayamada, Kaoru Yamagata, Kei Sakata, Yoshiya Tanaka
「The relevance of mTORC1-phosphorylated CXCR3+ memory B cells to the thogenesis of rheumatoid arthritis」
43. Seunghyun Lee, Shingo Nakayamada, Satoshi Kubo, Kaoru Yamagata, Hiroko Yoshinari, Yoshiya Tanaka
「Baricitinib inhibits the IL-23/STAT3 activation signal in Th17 cells from patients with systemic lupus erythematosus」
44. Yuichi Ishikawa, Kazuhisa Nakano, Hiroko Miyata, Yoshiya Tanaka
「Estimation of treatment and prognostic factors of pneumocystis pneumonia in Patients with Patients with connective tissue diseases: an analysis of a national administrative database in Japan」
45. Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Hiroko Yoshinari, Yoshino Inoue, Naoaki Ohkubo, Yoshiya Tanaka
「Effects of JAK inhibitors on immune phenotypes of peripheral lymphocytes in patients with rheumatoid arthritis, from FLOW study」
46. Shunsuke Fukuyo, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Ayako Yamaguchi, Ippei Miyagawa, Yusuke Miyazaki, Akio Kawabe, Yoshiya Tanaka
「15-year risk management for biologic and targeted synthetic DMARDs for treatment of RA -FIRST registry-」
47. Kaoru Yamagata, Shingo Nakayamada, Tong Zhang, Gulzhan Trimova, Phuong Anh Nguyen, Fumi

Uemura, Ippei Miyagawa, Shigeru Iwata, Yoshiya Tanaka

「A novel role of epigenetic dysregulation of ubash3a in the pathogenesis of rheumatoid arthritis (RA) ICW15-5」

48. Shigeru Iwata, Mingzeng Zhang, Maiko Hajime, Naoaki Ohkubo, Yasuyuki Todoroki, Hiroko Miyata, Kazuhisa Nakano, Shingo Nakayamada, Kaoru Yamagata, Kei Sakata, Yoshiya Tanaka

「Role of amino acid cystine in cytotoxic effects of CD8+ cells and the relevance to pathological processes of rheumatoid arthritis」

49. 吉成紘子、中野和久、宮川一平、中山田真吾、岩田 慈、山口絢子、河邊明男、宮崎佑介、井上嘉乃、大久保直紀、神田友梨恵、轟 泰幸、宮田寛子、上野匡庸、永安 敦、日下勝秀、田中良哉

「当科におけるベーチェット病の関節炎の特徴」

50. 井上嘉乃、中野和久、中山田真吾、岩田 慈、花見健太郎、福與俊介、久保智史、宮川一平、山口絢子、宮崎佑介、河邊明男、吉成紘子、齋藤和義、田中良哉

「関節リウマチ(RA)におけるトファシニブ(Tofa)による寛解および寛解維持に寄与する因子の検討 ～FIRST registry より～」

51. 中野和久、齋藤 和義、

「MTX 治療中の RA 患者に発生したリンパ増殖性疾患退縮後の RA 治療についての検討」

52. 中山田真吾

「全身性エリテマトーデスの治療戦略におけるベリムマブの位置づけ」

4. 中山田真吾

「大型血管炎の治療における IL-6 標的の意義」

5. 中野和久

「滑膜から考える関節リウマチにおける TNF α 中和の意義」

第 84 回日本皮膚科学会東京支部学術大会(シンポジウム) WEB

52. 田中良哉

「生物学的製剤の進歩」

第 117 回日本内科学会総会・講演会(シンポジウム) WEB

53. 田中良哉

「難治性リウマチ・免疫疾患治療の最前線」

第 117 回 日本内科学会総会・講演会 WEB

54. 宮崎佑介、中山田真吾、井上嘉乃、久保智史、中野和久、岩田 慈、河邊明男、吉成紘子、田中良哉

「IgG4 関連疾患における免疫フェノタイプ解析による病原性細胞と治療標的の同定」

55. 黒住 旭、岡田洋右、成澤 学、鳥本桂一、宮崎佑介、久保智史、中山田真吾、田中良哉

「バセドウ病の末梢血リンパ球フェノタイプ解析による薬剤抵抗性患者の選別に関する検討」

第 41 回日本炎症再生医学会 WEB

56.田中 良哉, Di Paolo J. A., Downie Bryan, Meng A., Mollova N., Yu Y., Han P

「Evaluation of potential mechanisms underlying the safety observations of filgotinib (FIL) in clinical studies in rheumatoid arthritis (RA)」

57.山形 薫, 中山田真吾, 上村 芙美, 岩田 慈, 田中良哉

「関節リウマチ患者の CD4 陽性 T 細胞における ubash3a 遺伝子のエピジェネティック制御と炎症誘導機構の解明」

58.Hao He, 中山田真吾, 山形 薫, 大久保直紀, 岩田 慈, 田中良哉

「IL-2 drives conversion of Tfh cells to Tfr cells through epigenetic modification in systemic lupus Erythematosus」

第 63 回日本糖尿病学会 WEB

59.羽生桃子

「2 型糖尿病患者におけるデュラグルチドの腎機能への影響についての検討」

60.得津明美

「Ambulatory Glucose Profile における血糖変動幅と CGM 指標との関係」

61.田中健一

「2 型糖尿病患者におけるマートニン値と動脈硬化、糖尿病血管合併症との関連についての検討」

62.黒住 旭

「FGM を用いた 1 型糖尿病における SGLT-2 阻害薬による短期的血糖改善効果の検討」

第 48 回日本臨床免疫学会総会・学術集会 WEB

63.Yoshiya Tanaka, Thomas Dörner, Michelle Petri Josef S.Smolen, Ernst R. Dow, Richard E. Higgs, Guilherme Rocha, Robert J. Benschop, Maria E. Silk, Stephanie de Bono, Robert W Hoffman

「全身性エリテマトーデス患者を対象とした 24 週第 2 相臨床試験におけるバリシチニブによる遺伝子発現変化に基づく JAK/STAT 及び IFN 応答遺伝子発現抑制を介した作用機序の解明」

64.田中良哉, 松木大造, 尾上朋弘, 秋山翔子, 溝端宏子, 安井大策, 佐藤玲子, 本間祐児, 大高有貴, Diaz-Decaro John, Chen Jing

「Burden of potential immune mediated diseases (pIMDs) in a Japanese population: A payer-claims database cohort study」

65.Hao He, 中山田真吾, 山形 薫, 大久保直紀, 岩田 慈, 田中良哉

「IL-2 drives conversion of Tfh cells to Tfr cells through epigenetic modification in systemic lupus erythematosus」

66.井上嘉乃, 久保智史, 中山田真吾, 中野和久, 岩田 慈, 花見健太郎, 福與俊介, 宮川一平, 宮崎佑介, 河邊明男, 田中良哉

「IgG4 関連疾患 (IgG4-RD) におけるフラクタルカイン受容体 (CX3CR1) 陽性ヘルパー T 細胞の意義」

67.大久保直紀, 岩田 慈, 中野和久, 中山田真吾, 花見健太郎, 福與俊介, 宮川一平, 山口絢子, 河邊明男, 宮崎佑介, 吉成紘子, 田中良

「ループス腎炎に対するミコフェノール酸モフェチル(MMF)の寛解導入療法の効果 ～LOOPS registry
より～」

68.轟 泰幸, 岩田 慈, 元 舞子, 張 明増, 上野匡庸, 中野和久, 中山田真吾, 田中良哉
「全身性エリテマトーデスにおける T-bet+CD11c+ B 細胞の分化誘導機構の解明 -免疫細胞代謝の
観点から-」

69.吉成紘子, 中山田真吾, 中野和久, 岩田 慈, 花見健太郎, 福與俊介, 宮川一平, 久保智史,
山口絢子, 宮崎佑介, 河邊明男, 大久保直紀, 井上嘉乃, 神田友梨恵, 轟 泰幸, 宮田寛子, 田
中良哉

「SLE 患者に対するベリムマブ治療による末梢血免疫フェノタイプの変化 ～LOOPS registry～」

70. 宮崎佑介, 中山田真吾, 井上嘉乃, 大久保直紀, 中野和久, 岩田 慈, 宮川一平, 山口絢子,
河邊明男, 吉成紘子, 田中良哉

「トシリズマブが大血管炎患者の免疫フェノタイプに与える影響～FLOW study～」

第 48 回日本臨床免疫学会総会・学術集会(ランチョンセミナー) WEB

71.中山田真吾, 宮崎佑介, 田中良哉

「全身性エリテマトーデスの免疫異常と長期治療戦略」

72.中野和久

「LS1-2 トシリズマブによる関節リウマチ治療の最適化」

第 48 回日本臨床免疫学会総会・学術集会(ワークショップ) WEB

73.岩田 慈

「全身性エリテマトーデス (SLE)におけるリンパ球免疫代謝異常と病態への関与」

第 48 回日本臨床免疫学会総会・学術集会(シンポジウム) WEB

74.中山田真吾, 大久保直紀, 宮崎佑介, 田中良哉

「成人 Still 病の病態と免疫異常」

75. 中野和久, 田中良哉

「自己免疫疾患におけるエピジェネティクス」

第 35 回日本糖尿病合併症学会 WEB

76.田中健一

「2 型糖尿病患者におけるメイトニンと糖尿病血管合併症との関連についての検討」

日本臨床内分泌代謝 Update 2020 WEB

77.齋藤 桃, 岡田 洋右, 田中 健一, 田中 良哉

「ニボルマブによる遅発性 irAE と考えられた ACTH 単独欠損症の 1 例」

78.羽生 桃子、岡田 洋右、田中 健一、田中 良哉

「デュロキセチン投与により急激に低 Na 血症が進行した SIADH の症例」

79.得津 明美、岡田 洋右、黒住 旭、田中 良哉

「SGLT2 阻害薬による糖尿病ケトアシドーシスを契機に SPIDDM と診断した 1 例」

第 331 回日本内科学会九州地方会 WEB

80.齋藤 桃、岡田洋右、田中健一、田中良哉

「インスリン配合注 2 回打ちからの段階的治療が週 1 回 GLP-1 製剤への切り替えに有効であった 2 型糖尿病の 1 例」

第 61 回九州リウマチ学会(ランチョンセミナー) WEB

81.田中良哉

「PF-ILD の新しい概念と膠原病リウマチに伴う間質性肺疾患に対する最新治療」

第 61 回九州リウマチ学会(アフタヌーンセミナー) WEB

82.上野 匡庸

「当院におけるメボリズマブの臨床経験」

第 61 回九州リウマチ学会 WEB

83.小坂峻平、中野和久、岩田 慈、宮崎佑介、河邊明男、吉成紘子、中山田真吾、田中良哉

「Crohn 病合併高安動脈炎に対し、ウステキヌマブで長期寛解を得た 1 例」

84.日下勝秀、中野和久、中山田真吾、岩田 慈、河邊明男、宮崎佑介、小坂峻平、田中良哉

「肺高血圧症再燃を繰り返す成人発症 Still 病の一例」

85.藤田悠哉、中野和久、岩田 慈、中山田真吾、園本格士朗、宮崎佑介、河邊明男、吉成紘子、田中良哉

「SLE に IgG4 関連腎臓病を合併した一例」

86.上野匡庸、宮川一平、中野和久、岩田 慈、花見健太郎、福與俊介、久保智史、園本格士郎、宮崎佑介、河邊明男、吉成紘子、中山田真吾、田中良哉

「好酸球性多発血管炎性肉芽腫症(EGPA)に対する Corticosteroid(CS)併用メボリズマブ(MPZ)療法の有効性と安全性」

87.轟 泰幸、中野和久、宮崎佑介、中山田真吾、岩田 慈、花見健太郎、福與俊介、河邊明男、佐藤実、田中良哉

「抗 MDA5 抗体陽性皮膚筋炎の早期診断に有用な臨床的特徴の検討」

88.松永五月、中野和久、河邊明男、中山田真吾、岩田 慈、宮崎佑介、吉成紘子、田中良哉

「胸腔鏡下肺切除により肺非結核性抗酸菌症(肺 NTM)をコントロールし関節リウマチ治療を強化し得た一例」

89.植本優里、中野和久、吉成紘子、有富貴史、大中貴史、米澤昭仁、田中良哉

「同種末梢血幹細胞移植により寛解を得たトリソミー 8 陽性骨髄異形成症候群併腸管型ベーチェット病の

一例」

90.伊野和馬、中野和久、河邊明男、中山田真吾、岩田 慈、園本格士朗、宮崎佑介、吉成紘子、田中良哉

「低補体血症性蕁麻疹様血管炎が先行発症した IgG4 関連腎臓病の一例」

91.宮田寛子、石川雄一、中野和久、田中良哉

「全国 DPC データによる膠原病性疾患に合併した PCP 治療成績と予後因子に関する検討」

92.神田友梨恵、中野和久、吉成紘子、宮崎佑介、河邊明男、園本格士朗、岩田 慈、花見健太郎、福與俊介、中山田真吾、佐藤 実、田中良哉

「生体肺移植後に全身性強皮症に伴う皮膚硬化ならびに自己免疫異常が改善した一例」

93.名和田彩、中山田真吾、田中良哉

「ループス腎炎の腎生検組織における治療標的分子の免疫組織化学的研究」

94.有富貴史、名和田雅夫、姫野佳久、神田加壽子、名和田彩、齋藤和義、田中良哉

「不明熱の原因確定診断に難渋した胃癌合併顕微鏡的多発血管炎の一例」

95.神田龍一郎、中野和久、中山田真吾、岩田 慈、園本格士朗、河邊明男、宮崎佑介、吉成紘子、田中良哉

「腔鏡下肺上葉部分切除後に寛解した多発血管炎性肉芽腫症(GPA)の1例」

96.船田将史、中野和久、田中宏明、岩田 慈、園本格士朗、宮崎佑介、河邊明男、吉成紘子、中山田真吾、田中良哉

「RA における分子標的製剤導入前スクリーニング CT による肺 NTM 症のリスク管理
～FIRST registry～」

97.藤田悠哉、岩田 慈、中野和久、園本格士朗、吉成紘子、宮崎佑介、河邊明男、中山田真吾、吉村玲児、田中良哉

「NPSLE 評価・治療への工夫に向けた多面的アプローチ～LOOPS registry より～」

98.神田友梨恵、中野和久、宮崎佑介、河邊明男、吉成紘子、園本格士朗、岩田 慈、花見健太郎、福與俊介、中山田真吾、佐藤 実、田中良哉

「自己免疫性疾患に合併した進行性線維化を伴う間質性肺炎(PF-ILD)に対するニンテダニブの有効性と安全性」

99.大久保直紀、中野和久、岩田 慈、花見健太郎、福與俊介、園本格士朗、山口絢子、河邊明男、宮崎佑介、吉成紘子、中山田真吾、田中良哉

「実臨床における膠原病性血栓性血小板減少性紫斑病(TTP)に対するリツキシマブ(RTX)の効果」

100.河邊明男、中野和久、中山田真吾、岩田 慈、花見健太郎、福與俊介、山口絢子、宮崎佑介、吉成紘子、田中良哉

「高齢関節リウマチ患者における生物学的製剤の安全性と有効性の検討～FIRST registry より～」

101.宮崎佑介、中野和久、中山田真吾、岩田 慈、花見健太郎、福與俊介、園本格士朗、河邊明男、吉成紘子、井上嘉乃、田中良哉

「維持療法期の全身性エリテマトーデス患者におけるベリムマブの有効性と安全性～LOOPS registry～」

102.園本格士朗、中野和久、吉成紘子、河邊明男、宮崎佑介、山口絢子、岩田 慈、中山田真吾、田中良哉

「b/ts-DMARDs 投与患者におけるニューモシチス肺炎(PCP)発症抑制基準の有用性の検証 -
FIRST registry」